Фармакоэкономический анализ лечения артериальной гипертензии препаратами бисопролола на стационарном и амбулаторном этапах

Р. И. Ягудина · Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология · 2009

According to RCS (Shostak N.A. and other, 2008) [1], to the termination of hospital term of treatment (14 day) at application of Bisogamma (5-10 mg/days) target values the HELL have been reached at 60 %, and at application of Konkor (5-10 mg/days) at 46,7 % of patients. By the end of an out-patient stage (60 days) against reception of preparations bisoprolole with addition of small doses gidrochlortiazide (20 mg/days) the number of the patients who have reached of target figures of arterial pressure has made 93,3 % in Bisogamma group and 86,7 % in Konkor group. The results of pharmacoeconomic analysis the general expenses for treatment of 100 patients in two stages, of 60 days, at use of Bisogamma has made 909 798 rubles, and at application of Konkor 932 782 rubles. CER at treatment of Bisogamma to the termination of the hospital and out-patient periods of treatment has made 14738,9 and 9751,3, and for group Konkor 19027,6 and 10758,7 accordingly. From the pharmacoeconomic point of view the application of Bisogamma is method of treatment scientifically proved sick of an arterial hypertension of middle age. Clinical advantages of Bisogamma in comparison with Konkor (the efficiency estimated on number of cases of target arterial pressure) is accompanied by the essential economic gain which has made 22 984 rubles at treatment of 100 patients within 60 days, including hospital and out-patient stages. Proceeding from the received data, replacement from Konkor to Bisogamma will allow to treat in addition 2,5 % of patients that taking into account high prevalence of an arterial hypertension, on the scale of population will make 1 400 thousand persons.

Cited by 0 works.

Authors